Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teva sweden ab - sitagliptinmalat - filmdragerad tablett - 25 mg - sitagliptinmalat 33,23 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teva sweden ab - sitagliptinmalat - filmdragerad tablett - 50 mg - sitagliptinmalat 66,46 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teva sweden ab - sitagliptinmalat - filmdragerad tablett - 100 mg - sitagliptinmalat 132,92 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medochemie ltd - metforminhydroklorid; sitagliptinfosfatmonohydrat - filmdragerad tablett - 50 mg/850 mg - sitagliptinfosfatmonohydrat 64,25 mg aktiv substans; metforminhydroklorid 850 mg aktiv substans; natriumlaurilsulfat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medochemie ltd - sitagliptinfosfatmonohydrat - filmdragerad tablett - 100 mg - sitagliptinfosfatmonohydrat 128,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medochemie ltd - sitagliptinfosfatmonohydrat - filmdragerad tablett - 50 mg - sitagliptinfosfatmonohydrat 64,25 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medochemie ltd - sitagliptinfosfatmonohydrat - filmdragerad tablett - 25 mg - sitagliptinfosfatmonohydrat 32,125 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medochemie ltd - metforminhydroklorid; sitagliptinfosfatmonohydrat - filmdragerad tablett - 50 mg/1000 mg - natriumlaurilsulfat hjälpämne; metforminhydroklorid 1000 mg aktiv substans; sitagliptinfosfatmonohydrat 64,25 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.